-
1 Comment
Big Pharma Split Corp is currently in a long term uptrend where the price is trading 10.5% above its 200 day moving average.
From a valuation standpoint, the stock is 15.3% cheaper than other stocks from the Financial Services sector with a price to sales ratio of 23.2.
Based on the above factors, Big Pharma Split Corp gets an overall score of 2/5.
| Exchange | TO |
|---|---|
| CurrencyCode | CAD |
| ISIN | CA08934P1080 |
| Sector | Financial Services |
| Industry | Asset Management |
| Market Cap | 18M |
|---|---|
| PE Ratio | None |
| Target Price | 2 |
| Dividend Yield | 8.7% |
| Beta | 0.64 |
Big Pharma Split Corp is a closed ended equity mutual fund launched and managed by Harvest Portfolios Group Inc. It invests in the public equity markets across United States. The fund primarily invests in the Pharmaceutical sector. Big Pharma Split Corp was formed on September 15, 2017 and is domiciled in Canada.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for PRM.TO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
